AAAAAA

   
Results: 1-7 |
Results: 7
A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A Southwest Oncology GroupTrial (SWOG 9407)
Authors: Pienta, KJ Fisher, EI Eisenberger, MA Mills, GM Goodwin, JW Jones, JA Dakhil, SR Crawford, ED Hussain, MHA
Citation: Kj. Pienta et al., A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A Southwest Oncology GroupTrial (SWOG 9407), PROSTATE, 46(4), 2001, pp. 257-261
Phase II study of intravenous CI-958 in metastatic colorectal adenocarcinoma
Authors: Hoff, PM Ellerton, JA Dakhil, SR Winn, RJ Abbruzzese, JL Pazdur, R
Citation: Pm. Hoff et al., Phase II study of intravenous CI-958 in metastatic colorectal adenocarcinoma, AM J CL ONC, 23(6), 2000, pp. 602-604
Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial
Authors: Loprinzi, CL Kugler, JW Sloan, JA Mailliard, JA LaVasseur, BI Barton, DL Novotny, PJ Dakhil, SR Rodger, K Rummans, TA Christensen, BJ
Citation: Cl. Loprinzi et al., Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial, LANCET, 356(9247), 2000, pp. 2059-2063
Sequential biochemical modulation of fluorouracil with folinic acid, N-phosphonacetyl-L-aspartic acid, and interferon alfa-2a in advanced colorectal cancer
Authors: Royce, ME McGarry, W Bready, B Dakhil, SR Belt, RJ Goodwin, JW Gray, R Hoff, PM Winn, R Pazdur, R
Citation: Me. Royce et al., Sequential biochemical modulation of fluorouracil with folinic acid, N-phosphonacetyl-L-aspartic acid, and interferon alfa-2a in advanced colorectal cancer, J CL ONCOL, 17(10), 1999, pp. 3276-3282
Association of immune parameters with clinical outcome in stage III colon cancer: results of Southwest Oncology Group Protocol 9009
Authors: Holcombe, RF Jacobson, J Dakhil, SR Stewart, RM Betzing, KS Kannan, K Macdonald, JS
Citation: Rf. Holcombe et al., Association of immune parameters with clinical outcome in stage III colon cancer: results of Southwest Oncology Group Protocol 9009, CANCER IMMU, 48(9), 1999, pp. 533-539
Phase II study of Didemnin B in central nervous system tumors: A SouthwestOncology Group study
Authors: Taylor, SA Giroux, DJ Jaeckle, KA Panella, TJ Dakhil, SR Schold, SC
Citation: Sa. Taylor et al., Phase II study of Didemnin B in central nervous system tumors: A SouthwestOncology Group study, INV NEW DR, 16(4), 1998, pp. 331-332
Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hour continuous infusion weekly for three weeks in metastatic colorectal carcinoma
Authors: Pazdur, R Medgyesy, DC Winn, RJ Dakhil, SR Moore, DF Scalzo, A Hoff, PM Arbuck, SG Abbruzzese, JL
Citation: R. Pazdur et al., Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hour continuous infusion weekly for three weeks in metastatic colorectal carcinoma, INV NEW DR, 16(4), 1998, pp. 341-346
Risultati: 1-7 |